About Aarti Drugs Limited

Aarti Drugs Limited (ADL), part of the Aarti Group, was incorporated in 1984 with a clear vision of becoming a leading manufacturer of pharmaceutical ingredients. Over four decades, the Company has established itself as a key player in the production of Active Pharmaceutical Ingredients (APIs), formulations, specialty chemicals, and intermediates. Its operations span more than 100 countries, with a strong presence in both regulated and semi-regulated markets. ADL operates 14 manufacturing facilities across Maharashtra, Gujarat, and Himachal Pradesh, supported by two R&D centres at Tarapur and Turbhe. Subsidiaries include Pinnacle Life Science Private Limited in India, along with Pinnacle Chile SpA and Pharma Go SpA abroad. Over the years, ADL has marked several milestones—from US FDA approval of a facility in 2008, entry into formulations in 2014, surpassing Rs 2,500 crore in consolidated turnover in 2022, and expansion into dermatology and personal care in 2024.

Aarti Drugs Limited’s Business Segments

The Company’s portfolio is diversified across APIs, formulations, and specialty chemicals. APIs contribute the largest share of revenue, with a portfolio exceeding 50 molecules covering antibiotics, antiprotozoals, antifungals, anti-diabetics, anti-inflammatory, and cardiovascular drugs. ADL is a global leader in the production of Metformin, Metronidazole, Ketoconazole, Nimesulide, and fluoroquinolones. Formulations are developed through its wholly owned subsidiary Pinnacle Life Science, which operates a US FDA-certified facility in Baddi, Himachal Pradesh, and supplies across 90 countries. Specialty chemicals and intermediates, including benzene sulfonyl chloride and chlorosulphonation derivatives, support both backward integration and third-party sales. Geographically, about 35% of revenue in FY 2024-25 was derived from exports.

Aarti Drugs Limited Key Management

The leadership team combines technical expertise and long-standing industry experience:

• Shri Chandrakant V. Gogri – Chairman Emeritus

• Shri Prakash M. Patil – Chairman, Managing Director & CEO

• Shri Rashesh C. Gogri – Managing Director

• Shri Harshit M. Savla – Joint Managing Director

• Shri Harit P. Shah – Executive Director

• Shri Uday M. Patil – Executive Director

• Shri Narendra J. Salvi – Non-Executive Director

• Shri Adhish P. Patil – Chief Financial Officer & Chief Operating Officer

• Shri Rushikesh V. Deole – Company Secretary & Compliance Officer

Latest Updates on Aarti Drugs Limited

• Commencement of trial production at the Sayakha (Gujarat) facility for anti-diabetic APIs and intermediates.

• Ongoing stabilisation of a greenfield API project at Tarapur aimed at reducing import dependence on China.

• Entry into dermatology products through a new greenfield facility at Tarapur.

• Lifting of the US FDA import alert on the Tarapur API plant, restoring access to regulated markets like the US, Western Europe, and Canada.

• Strengthening of the R&D pipeline with 15 oncology products under development, alongside antifungal, cardiac, diabetic, and dermatology therapies.

• Agreement with Prozeal Green Power to establish captive solar plants in Gujarat and Maharashtra, expected to generate over 50 million renewable energy units annually.

• Recognition of sustainability efforts with an EcoVadis Silver rating, placing ADL in the 89th percentile globally.